Search - tctmd.com

Displaying 21 - 40 of 291

Sort: Relevancy | Date

Don’t Skimp on Anticoagulation in Isolated Distal DVT: RIDTS

News Daily News

Don’t Skimp on Anticoagulation in Isolated Distal DVT: RIDTS

December 01, 2022

Nuisance Bleeds on DAPT Not Just an Annoyance: TALOS-AMI Analysis

News Daily News

Nuisance Bleeds on DAPT Not Just an Annoyance: TALOS-AMI Analysis

November 30, 2022

Many ESC Guideline Recommendations Out of Reach in Poorer Regions

News Daily News

Many ESC Guideline Recommendations Out of Reach in Poorer Regions

Michael O'Riordan

November 29, 2022

Vitamin D Doesn’t Reduce Statin-Associated Muscle Symptoms VITAL

News Daily News

Vitamin D Doesn’t Reduce Statin-Associated Muscle Symptoms: VITAL

Michael O'Riordan

November 25, 2022

Slight Risk of Interstitial Lung Disease Seen With Certain DOACs

News Daily News

Slight Risk of Interstitial Lung Disease Seen With Certain DOACs

November 23, 2022

P2Y12 Inhibitors Top Aspirin Following Post-PCI DAPT: Network Meta-analysis

News Daily News

P2Y12 Inhibitors Top Aspirin Following Post-PCI DAPT: Network Meta-analysis

November 21, 2022

Single-Center Study Offers Insights for Ticagrelor vs Prasugrel in Chronic CAD

News Daily News

Single-Center Study Offers Insights for Ticagrelor vs Prasugrel in Chronic CAD

Yael L. Maxwell

November 21, 2022

Exposure to Lead Linked to Risk of CVD Mortality: Strong Heart Study

News Daily News

Exposure to Lead Linked to Risk of CVD Mortality: Strong Heart Study

Michael O'Riordan

November 18, 2022

How Lp(a) Levels Compare With LDL-C in FH: Some Surprises

News Daily News

How Lp(a) Levels Compare With LDL-C in FH: Some Surprises

Michael O'Riordan

November 17, 2022

Novel Aldosterone Synthase Inhibitor Drops BP: Top-line Phase II Results

News Daily News

Novel Aldosterone Synthase Inhibitor Drops BP: Top-line Phase II Results

November 16, 2022

Many STEMI Patients Not Treated Within National Time Goals

News Daily News

Many STEMI Patients Not Treated Within National Time Goals

Michael O'Riordan

November 15, 2022

Drug Preconditioning Before CABG, Valve Surgery Shows Promise: START

News Conference News AHA 2022

Drug Preconditioning Before CABG, Valve Surgery Shows Promise: START

November 14, 2022

‘Agnostic’ EHR Alerts Boost VTE Prophylaxis in Hospitals and Postdischarge

News Conference News AHA 2022

‘Agnostic’ EHR Alerts Boost VTE Prophylaxis in Hospitals and Postdischarge

November 11, 2022

Cangrelor After Ticagrelor Pretreatment in ACS Might Be OK: SWAP-5

News Conference News AHA 2022

Cangrelor After Ticagrelor Pretreatment in ACS Might Be OK: SWAP-5

Yael L. Maxwell

November 11, 2022

Partial Oral Antibiotic Regimen for Endocarditis Effective in Real World

News Conference News AHA 2022

Partial Oral Antibiotic Regimen for Endocarditis Effective in Real World

Michael O'Riordan

November 10, 2022

Chinese Medicine Tongxinluo Yields ‘Surprising’ Benefits Post-STEMI: CTS-AMI

News Conference News AHA 2022

Chinese Medicine Tongxinluo Yields ‘Surprising’ Benefits Post-STEMI: CTS-AMI

November 10, 2022

RESPECT-EPA: Missed Primary Endpoint but Hints of Benefit With Icosapent Ethyl

News Conference News AHA 2022

RESPECT-EPA: Missed Primary Endpoint but Hints of Benefit With Icosapent Ethyl

November 10, 2022

Another OPTION? Indobufen Noninferior to Aspirin Following Successful PCI

News Conference News AHA 2022

Another OPTION? Indobufen Noninferior to Aspirin Following Successful PCI

Yael L. Maxwell

November 10, 2022

Endothelin Receptor Antagonist Effective in Resistant Hypertension: PRECISION

News Conference News AHA 2022

Endothelin Receptor Antagonist Effective in Resistant Hypertension: PRECISION

Michael O'Riordan

November 09, 2022

Four Drugs, One Pill: QUARTET USA Supports New Strategy for BP-Lowering

News Conference News AHA 2022

Four Drugs, One Pill: QUARTET USA Supports New Strategy for BP-Lowering

November 08, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.